Moleculomics to develop Covid-19 drug discovery platform

Moleculomics, based at Swansea University Medical School,
has been awarded funding from Innovate UK – the UK’s innovation agency, for
technology development to find drug treatments for Covid-19 and other viral
threats. The new in silico platform, GRASP – Generic Rapid Antiviral
Screening Platform, will seek to get ahead of emerging strains of the virus by
simulating the effects of mutations before they happen,

British Yeast Group 2016

The British Yeast Group Meeting 2016

The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.

During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts

Moleculomics Sponsors the British Science Festival 2016

Moleculomics Sponsors the British Science Festival 2016

Moleculomics were proud to sponsor the 2016 British Science Festival, hosted by Swansea University this year.

The British Science Festival is Europe’s longest-standing national event which connects people with scientists, engineers, technologists and social scientists. Organised by the British Science Association (BSA), the event was first held in York in 1831 and then annually at cities across the UK. 

Proteome scale structural bioinformatics platforms in drug discovery

Proteome scale structural bioinformatics platforms in drug discovery

Moleculomics founder and CEO Dr Jonathan Mullins was proud to be invited as keynote speaker at the International conference on Clinical Sciences and Drug Discovery (CSDD-2016) in Dundee earlier this year.

Highly aligned to the evolution of Moleculomics, the focus of CSDD-2016 lies in the translation of academic research findings into industry-driven drug development.

An image of some test tubes in the laboratory

Moleculomics Identify Novel Host-Pathogen Interaction Drug Targets

Moleculomics, a company who specialise in high-throughput prediction of molecular interactions using cutting-edge in silico modelling and screening tools, has recently completed a project funded by the Defence Science and Technology Laboratory’s (Dstl) Centre for Defence Enterprise (CDE). It focuses on the identification of host-pathogen interactions which can be manipulated in order to devise novel therapies to meet the UK’s current and future defence and security needs.

Development and evaluation of in silico toxicity screening panels: Presentation

We recently presented a poster at the 2nd Annual Drug Discovery USA Congress, 29-30 October 2015, Boston, USA. You can view the poster below and you can then use the left and right arrow keys on your keyboard to progress through the presentation and view the poster.

Alternatively, you may download the poster in pdf format using the following link

Montreal Skyline

Moleculomics to develop cutting-edge expertise in Greater Montréal

Moleculomics, a company specializing in molecular research for the pharmaceutical, defence and biotech industries, announced the opening of its first North American facility in Greater Montréal.

Founded just four years ago in Wales, the U.K.-based company develops computing biosimulation (in silico modelling) tools and data platforms to improve knowledge of molecular interactions in new drugs and chemical compounds.